The purpose of this study is to compare early intervention with Venetoclax and Obinutuzumab vs delayed therapy in newly diagnosed asymptomatic high0risk patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). You must have been diagnosed with CLL or SLL within the last 12 months.
Contact phone
Carolyn Krahulik | 517.364.2811
Contact email
cancerclinicaltrials@sparrow.org
Principal investigator
Dr. Gordan Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Hematology
Webform